Your browser doesn't support javascript.
loading
Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant.
Tamura, Tomokazu; Irie, Takashi; Deguchi, Sayaka; Yajima, Hisano; Tsuda, Masumi; Nasser, Hesham; Mizuma, Keita; Plianchaisuk, Arnon; Suzuki, Saori; Uriu, Keiya; Begum, Mst Monira; Shimizu, Ryo; Jonathan, Michael; Suzuki, Rigel; Kondo, Takashi; Ito, Hayato; Kamiyama, Akifumi; Yoshimatsu, Kumiko; Shofa, Maya; Hashimoto, Rina; Anraku, Yuki; Kimura, Kanako Terakado; Kita, Shunsuke; Sasaki, Jiei; Sasaki-Tabata, Kaori; Maenaka, Katsumi; Nao, Naganori; Wang, Lei; Oda, Yoshitaka; Ikeda, Terumasa; Saito, Akatsuki; Matsuno, Keita; Ito, Jumpei; Tanaka, Shinya; Sato, Kei; Hashiguchi, Takao; Takayama, Kazuo; Fukuhara, Takasuke.
Afiliação
  • Tamura T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Irie T; Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Deguchi S; School of Medicine, Hokkaido University, Sapporo, Japan.
  • Yajima H; Institute for the Advancement of Higher Education, Hokkaido University, Sapporo, Japan.
  • Tsuda M; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
  • Nasser H; One Health Research Center, Hokkaido University, Sapporo, Japan.
  • Mizuma K; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Plianchaisuk A; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
  • Suzuki S; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Uriu K; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Begum MM; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Shimizu R; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Jonathan M; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Suzuki R; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Kondo T; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Ito H; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Kamiyama A; Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Yoshimatsu K; School of Medicine, Hokkaido University, Sapporo, Japan.
  • Shofa M; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
  • Hashimoto R; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Anraku Y; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Kimura KT; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Kita S; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Sasaki J; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Sasaki-Tabata K; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Maenaka K; Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Nao N; School of Medicine, Hokkaido University, Sapporo, Japan.
  • Wang L; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
  • Oda Y; School of Medicine, Hokkaido University, Sapporo, Japan.
  • Ikeda T; Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Saito A; Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Matsuno K; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
  • Ito J; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan.
  • Tanaka S; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
  • Sato K; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Hashiguchi T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Takayama K; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Fukuhara T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Nat Commun ; 15(1): 1176, 2024 Feb 08.
Article em En | MEDLINE | ID: mdl-38332154
ABSTRACT
Circulation of SARS-CoV-2 Omicron XBB has resulted in the emergence of XBB.1.5, a new Variant of Interest. Our phylogenetic analysis suggests that XBB.1.5 evolved from XBB.1 by acquiring the S486P spike (S) mutation, subsequent to the acquisition of a nonsense mutation in ORF8. Neutralization assays showed similar abilities of immune escape between XBB.1.5 and XBB.1. We determine the structural basis for the interaction between human ACE2 and the S protein of XBB.1.5, showing similar overall structures between the S proteins of XBB.1 and XBB.1.5. We provide the intrinsic pathogenicity of XBB.1 and XBB.1.5 in hamsters. Importantly, we find that the ORF8 nonsense mutation of XBB.1.5 resulted in impairment of MHC suppression. In vivo experiments using recombinant viruses reveal that the XBB.1.5 mutations are involved with reduced virulence of XBB.1.5. Together, our study identifies the two viral functions defined the difference between XBB.1 and XBB.1.5.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Nat Commun Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Nat Commun Ano de publicação: 2024 Tipo de documento: Article